WVP
CYTH

Worth Venture Partners’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Worth Venture Partners’s Portfolio CYTH Stock Details CYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-88,690
Closed -$386K – 137
2020
Q4 		$386K Buy
+88,690
New +$416K 0.31% 68

Other funds holding CYTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Worth Venture Partners's CYTH Position: Q1 2021 in Review

Worth Venture Partners sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2021, closing a stake of 88,690 shares — an estimated $386K sold.

Worth Venture Partners first reported a position in CYTH in Q4 2020 and held it in 1 quarter. The position peaked at $386K in Q4 2020. 9 funds tracked by Wall St. Rank hold CYTH as of Q1 2021.

  • Worth Venture Partners reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Worth Venture Partners sold 88,690 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $386K.
  • Worth Venture Partners first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Worth Venture Partners's Cyclo Therapeutics, Inc. Common Stock position peaked at $386K in Q4 2020.
  • 9 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Worth Venture Partners's 13F filing for Q1 2021, filed 17 May 2021.